Genotoxic and Cytotoxic Damage by Cyclophosphamide and Adriamycin as a Response to Treatment in Breast Cancer Patients: Pilot Study

Jimena Garibay-Garcia¹, Fernando Mejia-Sanchez¹, Eduardo Ramírez-San-Juan², Miriam V. Flores-Merino¹, Julieta Castillo-Cadena¹

¹Research Center in Medical Science, Autonomous University of the State of Mexico, Toluca, Mexico.
²National School in Biological Science, Instituto Politécnico Nacional, Mexico City, Mexico.

DOI: 10.4236/jct.2015.62018                

Abstract

The aim of this study was to evaluate the genotoxicity induced by cyclophosphamide-adriamycin treatment in breast cancer patients through the frequencies of Sister Chromatid Exchange (SCE), Replication Index (RI), Mitotic Index (MI) and Cell Proliferation Index (CPI) and to study the possible association between biomarkers of genotoxicity and the early response to treatment. The frequencies were obtained before and immediately after therapy from 17 patients with breast cancer (p < 0.001). Response to treatment was assessed after two years resulting in 12 patients in a state of remission. MI and CPI had high values after treatment in women with active cancers compared to those in a state of remission, however there were not significant differences. Conclusions: It is possible that MI y CPI biomarkers can serve as indicators for early assessment of treatment with cyclophosphamide-adriamycin. It should be noted that these are preliminary results and further study is necessary.

Keywords

Sister Chromatid Exchange, Genotoxicity Biomarkers, Breast Cancer, Cyclophosphamide, Adriamycin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Mohar, A., Bargallo, E., Ramírez, M.T., Lara, F. and Beltrán-Ortega, A. (2009) Recursos disponibles para el tratamiento del cáncer de mama en México. Salud Pública de México, 51, 263-269. http://dx.doi.org/10.1590/S0036-36342009000800017
[2]	Knaul, F.M., Nigenda, G., Lozano, R., Arreola-Ornelas, H., Langer, A. and Frenk, J. (2009) Cáncer de mama en México: Una prioridad apremiante. Salud Pública de México, 51, 335-344. http://dx.doi.org/10.1590/S0036-36342009000800026
[3]	Bland, I.K. and Copeland, E.M. (2000) La mama, manejo multidisciplinario de las enfermedades benignas y malignas. Médica Panamericana, Buenos Aires.
[4]	Khosravi-Shahi, P., Izarzugaza-Perón, Y., Encinas-García, E., Díaz-Mu?oz-de-la-Espada, V.M. and Pérez Manga, G. (2008) Tratamiento adyuvante en el cáncer de mama operable. Anales de Medicina Interna, 25, 36-40. http://dx.doi.org/10.4321/S0212-71992008000100010
[5]	Rodríguez-Reyes, R.G. (2000) Persistencia de las lesiones causadas al ADN por agentes alquilantes, involucradas en la producción de intercambios de cromátides hermanas. Revista Especializada en Ciencias de la Salud, 3, 3-13.
[6]	Katzung, B.G. (1996) Farmacología Básica y Clínica. El Manual Moderno, México.
[7]	Arce, C., Martínez-Tlahuel, J. and Lara, F.U. (2006) Quimioterapia adyuvante en cáncer de mama: Presente y futuro. Cancerología, 1, 177-185.
[8]	Banerjee, A. and Benedict, W.F. (1979) Production of Sister Chromatid Exchanges by Various Cancer Chemotherapeutic Agents. Cancer Research, 39, 797-799.
[9]	López-Nigro, M.M. and Carballo, M.A. (2008) Los nitroimidazoles como modelo de mutagénesis química y muerte celular. Theoria, 17, 47-62.
[10]	Uribe-Alcocer, M. and Díaz-Jaimes, J.P. (2001) Fish Chromosomes as Biomarkers of Genotoxic Damage and Proposal for the Use of Tropical Catfish Species for Short-Term Screening of Genotoxic Agents. Environmental Science Research, 56, 361-390.
[11]	Brugés, R., Guzmán, L.H., Sánchez, O., Díaz, S. and Vergara, E. (2009) Neoadyuvancia en cáncer de mama. Revista Colombiana de Cancerología, 13, 157-174. http://dx.doi.org/10.1016/S0123-9015(09)70134-9
[12]	Jones, S.E., Durie, B.G.M. and Salmon, S.E. (1975) Combination Chemotherapy with Adriamycin and Cyclophosphamide for Advanced Breast Cancer. Cancer, 36, 90-97. http://dx.doi.org/10.1002/1097-0142(197507)36:1<90::AID-CNCR2820360104>3.0.CO;2-H
[13]	SEGOB (2012) Norma oficial mexicana NOM-012-SSA3-2012, Que establece los criterios para la ejecución de proyectos de investigación para la salud en seres humanos. http://dof.gob.mx/nota_detalle.php?codigo=5284148&fecha=04/01/2013
[14]	WMA (2013) Helsinki Declaration. http://www.wma.net/es/30publications/10policies/b3/
[15]	Moorhead, P.S., Nowell, P.C., Mellman, W.J., Battips, D.M. and Hungerford, D.A. (1960) Chromosome Preparations of Leukocytes Cultured from Human Peripheral Blood. Experimental Cell Research, 20, 613-616. http://dx.doi.org/10.1016/0014-4827(60)90138-5
[16]	Perry, P. and Wolff, S. (1974) New Giemsa Method for the Differential Staining of Sister Chromatids. Nature, 251, 156-158. http://dx.doi.org/10.1038/251156a0
[17]	Krishna, G., Xu, J., Nath, J., Petersen, M. and Ong, T. (1985) In Vivo Cytogenic Studies on Mice Exposed to Ethylene Dibromide. Mutation Research/Genetic Toxicology, 158, 81-87. http://dx.doi.org/10.1016/0165-1218(85)90101-6
[18]	Pérez-Herrera, N., Ceballos-Quintal, J.M. and Pinto-Escalante, D. (1996) Prevalencia de intercambio de cromátides hermanas en una población libre de exposición a agentes clastogénicos. Revista Biomédica, 10, 71-76.
[19]	Ostrosky-Wegman, P. and Gonsebatt, M.E. (1997) Biomarcadores moleculares en la determinación de efectos xenobióticos. Gaceta Médica de México, 133, 93-96.
[20]	Ocampo, A.P., Hoyos, L.S. and Carvajal, S. (2001) Medición del da?o genético inducido por el Basuco en linfocitos humanos empleando la prueba de micronúcleos con citocalasina b. Acta Biológica Colombiana, 6, 59-66.
[21]	Poblete, M.T. (2002) Marcadores de utilidad en cáncer mamario. Cuadernos de Cirugía, 15, 74-79. http://dx.doi.org/10.4206/cuad.cir.2001.v15n1-14
[22]	Figueroa, L., Bargallo, E., Castorena, G. and Valancia, S. (2009) Cáncer de mama familiar, BRCA1 positivo. Revista Chilena de Cirugía, 61, 547-551. http://dx.doi.org/10.4067/S0718-40262009000600010
[23]	Hick, A.S., Paczkowski, M.G., Gadano, B.A. and Carballo, M.A. (2007) Biomarcadores de genotoxicidad en individuos expuestos a arsénico. Latin American Journal of Pharmacy, 26, 691-699.
[24]	Gallardo, J., Rubio, B., Baraja, O., González, C. and Cunill, E. (2001) Quimioterapia en Cáncer de mama Qué drogas? Cuánto Cuántas? Revista Hospital Clínico Universidad de Chile, 12, 134-146.